The radioactive stents market is an emerging subsection of the global medical devices market. Radioactive stents are specialized stents used primarily in the treatment of coronary artery disease and other vascular disorders. Radioactive material, for instance, iridium-192 or phosphorus-32, is embedded in the design of radioactive stents, which emits controlled radiation to prevent restenosis (re-narrowing) of blood vessels when the stent is deployed. This stent is beneficial in reducing the risk of vessel closure, thus enhancing long-term patient outcomes.

The global radioactive stents market is anticipated to grow at a compound annual growth rate (CAGR) of 5.8% during the period from 2024 to 2031, and the market size will increase from US$ XX million in 2024 to US$ XX million in 2031. This growth is being driven by an increasing incidence of cardiovascular disease, advances in stent technology, the rising demand for minimally invasive treatments, and the growing adoption of retrograde stents as an alternative in certain complex cases

What Are Radioactive Stents?

Radioactive stents are medical stents placed inside narrowed or blocked arteries to maintain the normal course of blood. Radioactive stents are unique compared to other stents since they contain a layer of radioactive material on their surface that inhibits the artery from re-narrowing by inhibiting cell growth. Radioactive stents are unique compared to normal stents since they use low-dose radiation to inhibit the growth of smooth muscle cells on the stent, which is one of the most important causes of restenosis.

Key Market Drivers

Several drivers are fueling growth in the radioactive stents market:

• Increasing Prevalence of Cardiovascular Diseases: The rising incidence worldwide of coronary artery disease (CAD), heart attack, and other vascular illnesses is one of the primary reasons driving demand for innovative stent technology. Cardiovascular disease is the leading cause of death worldwide, said the World Health Organization (WHO). That rising cardiovascular disease burden is driving demand for more effective treatments like radioactive stents.

• Emerging Stent Design Technologies: Recent technological advancements have resulted in more efficient radioactive stents that have improved biocompatibility and less complications. Current radioactive stents are constructed with a greater precision level, thus lowering stent thrombosis and restenosis complications. These improvements are making radioactive stents increasingly popular among both physicians and patients, hence the market growth.

• Minimally Invasive Procedures: Minimally invasive treatments such as percutaneous coronary intervention (PCI) have gained increased popularity in the last few years due to short recovery periods and relative safety relative to complications as opposed to the traditional open method of surgery. The application of these treatments has generated growing demands for stents, particularly radioactive stents, as a pivotal element of minimally invasive therapies for coronary artery disease. 

Market Segmentation

The radioactive stent market can be segmented based on type, application, and geography.

By Product Type

• Retrograde Stents
• Antegrade Stents
• Internal Stents

By Application

• Lithotripsy
• Ureteroscopy
• Ureteroenoscopy
• Percutaneous Nephrolithotomy

Competitive Landscape

The radioactive stent market is competitive with numerous key players pushing the market. The firms are focusing on technology development, collaborations, and new product launches to maintain a competitive edge. Some of the prominent players in the market are:

• Abbott Laboratories
• Aetna Inc.
• Allium Medical Solutions Ltd.
• APC Cardiovascular Ltd.
• C.R. Bard
• Changzhou Zhiye Co Ltd.
• Cook Medical Inc.
• Medline Industries Ltd
• Micro-Tech Pvt. Ltd.

The global market for radioactive stents will develop at 5.8% CAGR from 2024 to 2031 and will increase from US$ XX million in 2024 to US$ XX million in 2031. Growth can be attributed to the growing prevalence of cardiovascular diseases, newer stent technology, and a high demand for minimally invasive procedures.

Conclusion

The radioactive stents market is expected to expand significantly with the increasing worldwide prevalence of cardiovascular diseases, technology advancements in stents, and the extensive use of minimally invasive procedures. With a growth rate of 5.8%, the market is expected to expand exponentially in the future and offer sufficient growth opportunities for the healthcare and medical device sectors. As the market continues to evolve, patient-centric and innovation-driven businesses will be emerging as the leaders in this fluid market.

FAQs

What are radioactive stents?

Radioactive stents are radioactive coatings on medical stents that are designed to suppress restenosis by emitting controlled radiation.

What is the radioactive stent market growth rate?

The radioactive stent market will grow at a CAGR of 5.8% from 2024 to 2031.

What are radioactive stents predominantly used for?

They are primarily used for treating coronary artery disease in both hospitals

Why are radioactive stents used?

Radioactive stents are used to prevent the re-narrowing of arteries after the placement of stents through controlled releases of radiation.

What are the most dominant firms selling radioactive stents in the market?

They are primarily represented by Medtronic, Boston Scientific, Abbott Laboratories, and Cordis Corporation.

Which market has the highest share for radioactive stents?

North America has the highest share because it has a well-developed healthcare infrastructure and high rates of cardiovascular diseases.

What are the drivers of the market for radioactive stents?

Rising cardiovascular diseases, technological innovation, and a preference for minimally invasive interventions are major drivers.